What's Behind Regeneron's Q1 Revenue and Earnings Misses

There was some good news for investors the last time Regeneron Pharmaceuticals (NASDAQ: REGN) reported its quarterly results. In February, the company announced that revenue rose 22% from the prior-year period while adjusted earnings increased by 29%.